PRECIDENTD (Type 2 Diabetes)

Purpose of this Study

We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.

Who Can Participate?

Eligibility

Adults with type 2 diabetes who:
  • Are ages 40+ and have had a heart attack, or a stroke, or have had stents placed to open their blood vessels; OR
  • Are ages 60+ and have hemoglobin AIC above 8, or have chronic kidney disease, or who smoke
For more information about this study, contact the study team at chad.harrell@duke.edu.

Age Range

40-80

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will get a random assignment (like a coin flip) to either:
  • Take an SGLT2 inhibitor; OR
  • Take a GLP-1 receptor agonist
SGLT2 inhibitors include the following medications: Jardiance®, Farxiga®, and Invokana®. GLP-1 receptor agonists include the following medications: Victoza®, Trulicity®, Ozempic®, and Rybelsus®. All drugs that are used in this study are FDA-approved for the treatment of type 2 diabetes.

Locations

Remote/online

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

PREvention of CardIovascular and DiabEtic kidNey disease in Type 2 Diabetes

Study Website

Study Website

Principal Investigator

William
Jones

Protocol Number

PRO00111165

NCT ID

NCT05390892

Phase

III

Enrollment Status

Open to Enrollment
ClinicalTrials.gov